Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Enphase Energy Inc (ENPH)

Enphase Energy Inc (ENPH)
63.09 +1.55 (+2.52%) 09:55 ET [NASDAQ]
62.90 x 119 63.17 x 38
Realtime by (Cboe BZX)
62.90 x 119 63.17 x 38
Realtime 62.67 +1.13 (+1.84%) 09:21 ET
Quote Overview for Mon, Mar 24th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
62.29
Day High
63.84
Open 62.59
Previous Close 61.54 61.54
Volume 97,259 97,259
Avg Vol 4,757,198 4,757,198
Stochastic %K 66.30% 66.30%
Weighted Alpha -49.18 -49.18
5-Day Change -0.61 (-0.96%) -0.61 (-0.96%)
52-Week Range 51.63 - 141.63 51.63 - 141.63
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,152,265
  • Shares Outstanding, K 132,471
  • Annual Sales, $ 1,330 M
  • Annual Income, $ 102,660 K
  • EBIT $ 77 M
  • EBITDA $ 150 M
  • 60-Month Beta 2.12
  • Price/Sales 6.14
  • Price/Cash Flow 39.35
  • Price/Book 10.01

Options Overview Details

View History
  • Implied Volatility 66.64% ( +0.07%)
  • Historical Volatility 59.54%
  • IV Percentile 59%
  • IV Rank 43.58%
  • IV High 90.18% on 10/15/24
  • IV Low 48.45% on 08/30/24
  • Put/Call Vol Ratio 0.18
  • Today's Volume 238
  • Volume Avg (30-Day) 25,283
  • Put/Call OI Ratio 0.99
  • Today's Open Interest 226,881
  • Open Int (30-Day) 284,004

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 36 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.36
  • Number of Estimates 13
  • High Estimate 0.45
  • Low Estimate 0.24
  • Prior Year -0.06
  • Growth Rate Est. (year over year) +700.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
51.63 +22.38%
on 03/04/25
Period Open: 66.08
67.20 -5.97%
on 02/25/25
-2.90 (-4.38%)
since 02/24/25
3-Month
51.63 +22.38%
on 03/04/25
Period Open: 73.28
76.90 -17.83%
on 01/07/25
-10.09 (-13.78%)
since 12/24/24
52-Week
51.63 +22.38%
on 03/04/25
Period Open: 114.61
141.63 -55.39%
on 06/12/24
-51.42 (-44.87%)
since 03/22/24

Most Recent Stories

More News
Canadian Solar to Supply 100 MW Battery Energy Storage in Arizona

Canadian Solar Inc.’s CSIQ e-STORAGE subsidiary has recently inked a Battery Supply Agreement and Long-Term Service Agreement with Strata Clean Energy's White Tank Energy Storage LLC to provide a 100-megawatt...

SOL : 1.6500 (-0.60%)
ENPH : 63.28 (+2.83%)
SEDG : 17.73 (+4.11%)
CSIQ : 10.34 (+3.82%)
Is First Solar Stock Underperforming the S&P 500?

First Solar has struggled to keep pace with the S&P 500 Index over the past year, yet analysts remain strongly optimistic about its future growth.

ENPH : 63.28 (+2.83%)
FSLR : 134.19 (+2.19%)
$SPX : 5,742.82 (+1.33%)
Q4 Earnings Highs And Lows: First Solar (NASDAQ:FSLR) Vs The Rest Of The Renewable Energy Stocks

Q4 Earnings Highs And Lows: First Solar (NASDAQ:FSLR) Vs The Rest Of The Renewable Energy Stocks

TPIC : 0.8845 (+5.93%)
ENPH : 63.28 (+2.83%)
FSLR : 134.19 (+2.19%)
AMSC : 21.57 (+8.72%)
BE : 24.32 (+1.54%)
Stock Market News For Mar 18, 2025

Market NewsWall Street closed higher on Monday as investors processed economic data and expected the Fed to maintain interest rates at its next meeting. The Nasdaq Composite, the Dow and the S&P 500 ended...

ENPH : 63.28 (+2.83%)
Enphase Energy Applauds New Rapid Shutdown Standard for Solar Installations in Brazil

ENPH : 63.28 (+2.83%)
Enphase Energy Launches Next-Generation IQ EV Charger across Europe

ENPH : 63.28 (+2.83%)
1 Small-Cap Stock with Solid Fundamentals and 2 to Turn Down

1 Small-Cap Stock with Solid Fundamentals and 2 to Turn Down

LIND : 9.95 (+2.68%)
ENPH : 63.28 (+2.83%)
AMPL : 11.75 (+0.86%)
Enphase Energy Increases Deployments of Legacy NEM System Expansion Solution in California

ENPH : 63.28 (+2.83%)
Enphase, Qualcomm, TSMC, Marvell, SealsQ: 5 Semi Stocks With Highest Retail Buzz Last Week

The semiconductor industry is buzzing with retail interest amid President Donald Trump’s tariff plans, a surge in energy demand, and a continued boom in artificial intelligence applications and usage....

LAES : 3.12 (+4.70%)
ENPH : 63.28 (+2.83%)
QCOM : 159.56 (+1.75%)
MRVL : 71.94 (+2.20%)
TSM : 180.46 (+2.11%)
Five Top Stocks for a Potential $25.54 Billion Vehicle-to-Grid Market

Investors should keep an eye on the vehicle-to-grid (V2G) market. Currently valued at $5.059 billion as of 2024, the market is expected to soar to $25.54 billion by 2029. All thanks to surging demand for...

ENPH : 63.28 (+2.83%)
SEDG : 17.73 (+4.11%)
NVVE : 1.6800 (+3.70%)
CHPT : 0.6908 (+0.79%)
SBGSY : 50.1000 (-0.08%)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023

/CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2 etripamil study...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023

/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

/CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals: Q2 Earnings Snapshot

Milestone Pharmaceuticals: Q2 Earnings Snapshot

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update

/CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update

/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet

- Primary endpoint met, with 64.3% of patients who self-administered etripamil converting from supraventricular tachycardia to sinus rhythm within 30 minutes...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023

/CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2 etripamil study...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023

/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

/CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals: Q2 Earnings Snapshot

Milestone Pharmaceuticals: Q2 Earnings Snapshot

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update

/CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update

/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet

- Primary endpoint met, with 64.3% of patients who self-administered etripamil converting from supraventricular tachycardia to sinus rhythm within 30 minutes...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023

/CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2 etripamil study...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023

/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

/CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals: Q2 Earnings Snapshot

Milestone Pharmaceuticals: Q2 Earnings Snapshot

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update

/CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update

/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

MIST : 2.1400 (+12.63%)
Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet

- Primary endpoint met, with 64.3% of patients who self-administered etripamil converting from supraventricular tachycardia to sinus rhythm within 30 minutes...

MIST : 2.1400 (+12.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Enphase Energy, Inc. is a global energy technology company that delivers energy management technology for the solar industry. It designs, develops, manufactures and sells home energy solutions, which connect energy generation, storage and control and communications management on one intelligent platform....

See More

Key Turning Points

3rd Resistance Point 65.05
2nd Resistance Point 63.97
1st Resistance Point 62.75
Last Price 63.28
1st Support Level 60.45
2nd Support Level 59.37
3rd Support Level 58.15

See More

52-Week High 141.63
Fibonacci 61.8% 107.25
Fibonacci 50% 96.63
Fibonacci 38.2% 86.01
Last Price 63.28
52-Week Low 51.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.